Xenon Pharmaceuticals (XENE) Up 2.4% Since Last Earnings Report: Can It Continue? [Yahoo! Finance]
Xenon Pharmaceuticals Inc. - Common Shares (XENE)
Last xenon pharmaceuticals inc. - common shares earnings: 11/5 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investor.xenon-pharma.com
Company Research
Source: Yahoo! Finance
Will the recent positive trend continue leading up to its next earnings release, or is Xenon Pharmaceuticals due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important catalysts. Xenonreported a loss of 81 cents per share for the third quarter of 2024, narrower than the Zacks Consensus Estimate of a loss of 82 cents. The company had incurred a loss of 73 cents per share in the year-ago quarter. In the reported quarter, Xenon did not generate any revenues. Due to the absence of a marketed product, the company only recognizes periodic collaboration revenues in its top line from its ongoing partnership with Neurocrinefor XEN901, now known as NBI-921352. The company did not recognize any revenues in the year-ago quarter as well. In the third quarter of 2024, research and development (R&D) expenses increased 33% to $57 million compared with $42
Show less
Read more
Impact Snapshot
Event Time:
XENE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
XENE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
XENE alerts
High impacting Xenon Pharmaceuticals Inc. - Common Shares news events
Weekly update
A roundup of the hottest topics
XENE
News
- Xenon Pharmaceuticals Inc. (NASDAQ: XENE) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $53.00 price target on the stock.MarketBeat
- Xenon Showcases New Long-Term Azetukalner Data from X-TOLE OLE Study in FOS at AES 2024 [Canadian Business Journal (Canada)]Canadian Business Journal
- Xenon Showcases New Long-Term Azetukalner Data from X-TOLE OLE Study in FOS at AES 2024 [Yahoo! Finance]Yahoo! Finance
- Xenon Showcases New Long-Term Azetukalner Data from X-TOLE OLE Study in FOS at AES 2024GlobeNewswire
- Xenon to Showcase New Long-Term Azetukalner Data at AES 2024 [Canadian Business Journal (Canada)]Canadian Business Journal
XENE
Earnings
- 11/12/24 - Beat
XENE
Sec Filings
- 12/19/24 - Form 4
- 12/18/24 - Form 144
- 11/22/24 - Form 4
- XENE's page on the SEC website